Rosuvastatin 20 mg Fenofibrate 160 mg tablet

ROSUROOT-F

Rosuvastatin 20 mg and Fenofibrate 160 mg Tablets

Division: DIABGLYM

Composition

Each film-coated tablet contains:

Rosuvastatin Calcium IP equivalent to Rosuvastatin — 20 mg

Fenofibrate IP — 160 mg

Excipients — q.s.

Colour: Approved colour used

Dosage form: Film-coated oral tablet

Product Description

ROSUROOT-F is a comprehensive lipid-lowering combination containing Rosuvastatin 20 mg and Fenofibrate 160 mg, formulated for the effective management of mixed dyslipidemia, diabetic dyslipidemia, hypertriglyceridemia, and patients with elevated LDL cholesterol and triglyceride levels. This combination provides dual lipid-modifying action by significantly reducing LDL cholesterol, triglycerides, VLDL cholesterol, and non-HDL cholesterol while improving HDL cholesterol levels.

Rosuvastatin is a potent HMG-CoA reductase inhibitor that effectively lowers LDL cholesterol and reduces cardiovascular risk, while Fenofibrate is a fibric acid derivative that primarily reduces triglycerides and improves atherogenic lipid abnormalities. Together, they provide superior lipid control in high-risk patients with diabetes, metabolic syndrome, obesity, cardiovascular disease, and mixed dyslipidemia.

ROSUROOT-F is particularly beneficial in patients with diabetic dyslipidemia where elevated triglycerides and low HDL cholesterol coexist with increased LDL cholesterol, a pattern strongly associated with accelerated atherosclerosis and cardiovascular complications.

Technical Knowledge of Rosuvastatin and Fenofibrate

Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol biosynthesis, leading to increased LDL receptor expression and enhanced clearance of circulating LDL cholesterol. It also reduces VLDL production and provides anti-inflammatory and plaque-stabilizing effects.

Fenofibrate activates Peroxisome Proliferator-Activated Receptor Alpha (PPAR-α), resulting in increased lipoprotein lipase activity, enhanced triglyceride-rich lipoprotein clearance, reduced hepatic VLDL synthesis, increased HDL production, and improved lipid metabolism.

The combination of Rosuvastatin and Fenofibrate offers complementary mechanisms that target both cholesterol and triglyceride abnormalities, providing comprehensive lipid management in high cardiovascular risk patients.

Mechanism of Action

Rosuvastatin reduces hepatic cholesterol synthesis, increases LDL receptor activity, lowers LDL cholesterol and total cholesterol, decreases VLDL production, and stabilizes atherosclerotic plaques.

Fenofibrate activates PPAR-α receptors, enhances lipoprotein lipase activity, reduces triglycerides and VLDL, increases HDL cholesterol, and improves overall lipid metabolism.

Key Benefits

Powerful reduction of LDL cholesterol

Significant triglyceride lowering

Improves HDL cholesterol levels

Reduces non-HDL cholesterol

Comprehensive management of mixed dyslipidemia

Beneficial in diabetic dyslipidemia

Supports cardiovascular risk reduction

Helps improve atherogenic lipid abnormalities

Suitable for long-term lipid management under medical supervision

Clinical Applications

ROSUROOT-F is commonly prescribed for mixed dyslipidemia, diabetic dyslipidemia, hypertriglyceridemia, combined hyperlipidemia, metabolic syndrome, cardiovascular risk reduction, atherosclerotic cardiovascular disease prevention, and patients with elevated LDL cholesterol and triglycerides.

Facts About Rosuvastatin and Fenofibrate

Rosuvastatin is one of the most potent statins available for LDL cholesterol reduction and has extensive evidence supporting cardiovascular risk reduction. Fenofibrate is particularly effective in reducing triglycerides and increasing HDL cholesterol. The combination is especially useful in diabetic patients with mixed dyslipidemia and elevated triglycerides, where comprehensive lipid control is essential for reducing residual cardiovascular risk.

Key Facts

Dual lipid-lowering combination therapy

Rosuvastatin 20 mg for intensive LDL reduction

Fenofibrate 160 mg for triglyceride control

Effective in diabetic and mixed dyslipidemia

Supports cardiovascular and metabolic risk reduction

Evidence-based combination therapy

Quality-assured pharmaceutical formulation

PCD Pharma Franchise Opportunity

ROSUROOT-F is an excellent product for PCD Pharma Franchise, Cardio-Diabetic Franchise, and Lipid Management Franchise across India. The rapidly increasing prevalence of diabetes, dyslipidemia, obesity, metabolic syndrome, and cardiovascular disease creates strong prescription demand and long-term market potential for this combination.

Why Choose ROSUROOT-F for PCD Pharma Franchise?

High prescription potential

Strong physician, cardiologist, and diabetologist acceptance

Attractive monopoly franchise opportunity

Competitive pricing

Promotional support available

Visual aids and marketing inputs

Consistent product quality

Excellent repeat business potential

Third Party Manufacturing

Chemsroot Pharmaceutical offers Third Party Manufacturing of Rosuvastatin and Fenofibrate Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.

Our Third Party Manufacturing Services Include

Private label manufacturing

Contract manufacturing

Custom brand manufacturing

Loan license manufacturing

DCGI-compliant production

GMP-certified manufacturing

Batch manufacturing documentation

Product registration support

Customized packaging and artwork

Monopoly franchise packaging

Bulk manufacturing capability

Manufacturing Features

Pharmaceutical-grade raw materials

IP/BP/USP quality standards

In-process quality control

Finished product testing

Stability-oriented formulation

Moisture-controlled tablet manufacturing

Blister and Alu-Alu packaging options

ROSUROOT-F from DIABGLYM combines intensive LDL cholesterol reduction, effective triglyceride control, comprehensive cardiovascular protection, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable and evidence-based lipid-lowering combination.